{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:05:48Z","timestamp":1775037948581,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11656-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:46:25Z","timestamp":1775029585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling"],"prefix":"10.1007","volume":"53","author":[{"given":"Bashdar Mahmud","family":"Hussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soudeh","family":"Ghafouri-Fard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"11656_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.02.002","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q et al (2025) Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Center. https:\/\/doi.org\/10.1016\/j.jncc.2025.02.002","journal-title":"J Natl Cancer Center"},{"key":"11656_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050723","author":"A Bhushan","year":"2021","unstructured":"Bhushan A, Gonsalves A, Menon JU (2021) Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13050723","journal-title":"Pharmaceutics"},{"key":"11656_CR3","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.clinsp.2025.100743","volume":"80","author":"BS Mota","year":"2025","unstructured":"Mota BS, Shimizu C, Reis YN, Gon\u00e7alves R, Soares Junior JM, Baracat EC et al (2025) Dense breasts and women\u2019s health: which screenings are essential? Clin (Sao Paulo) 80:100743","journal-title":"Clin (Sao Paulo)"},{"issue":"5","key":"11656_CR4","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/curroncol29050291","volume":"29","author":"PB Gordon","year":"2022","unstructured":"Gordon PB (2022) The impact of dense breasts on the stage of breast cancer at diagnosis: a review and options for supplemental screening. Curr Oncol 29(5):3595\u20133636","journal-title":"Curr Oncol"},{"issue":"52","key":"11656_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202406475","volume":"20","author":"D Ishwar","year":"2024","unstructured":"Ishwar D, Premachandran S, Das S, Venkatakrishnan K, Tan B (2024) Profiling breast tumor heterogeneity and identifying breast cancer subtypes through tumor-associated immune cell signatures and immuno nano sensors. Small 20(52):e2406475","journal-title":"Small"},{"issue":"6","key":"11656_CR6","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1097\/MS9.0000000000002075","volume":"86","author":"P Mohan Lal","year":"2024","unstructured":"Mohan Lal P, Hamza Siddiqui M, Soulat A, Mohan A, Tanush D, Tirath K et al (2024) MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review. Ann Med Surg (Lond) 86(6):3543\u201350","journal-title":"Ann Med Surg (Lond)"},{"key":"11656_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.768949","volume":"11","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Khanbabapour Sasi A, Abak A, Shoorei H, Khoshkar A, Taheri M (2021) Contribution of miRNAs in the pathogenesis of breast cancer. Front Oncol 11:768949","journal-title":"Front Oncol"},{"issue":"4","key":"11656_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ncrna.2023.09.003","volume":"8","author":"BM Hussen","year":"2023","unstructured":"Hussen BM, Abdullah KH, Abdullah SR, Majeed NM, Mohamadtahr S, Rasul MF et al (2023) New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets. Non-coding RNA Res 8(4):645\u201360","journal-title":"Non-coding RNA Res"},{"key":"11656_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111528","volume":"138","author":"BM Hussen","year":"2021","unstructured":"Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S (2021) MicroRNA: a signature for cancer progression. Biomed Pharmacother 138:111528","journal-title":"Biomed Pharmacother"},{"key":"11656_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158191","author":"D Barbagallo","year":"2024","unstructured":"Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal SA et al (2024) MiR-223-3p in cancer development and cancer drug resistance: same coin, different faces. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25158191","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11656_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83170-4","volume":"14","author":"M Shen","year":"2024","unstructured":"Shen M, Mao Y, Wang X, Huang J, Zhang Q, Zhang J (2024) LncRNA DNM1P35 sponges hsa-mir-326 to promote ovarian cancer progression. Sci Rep 14(1):31502","journal-title":"Sci Rep"},{"issue":"9","key":"11656_CR12","volume":"215","author":"M Zong","year":"2019","unstructured":"Zong M, Liu Y, Zhang K, J Y, Chen L (2019) The effects of miR-429 on cell migration and invasion by targeting Slug in esophageal squamous cell carcinoma. Pathology 215(9):152526","journal-title":"Pathology"},{"key":"11656_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155277","volume":"256","author":"S Ghafouri-Fard","year":"2024","unstructured":"Ghafouri-Fard S, Hussen BM, Eslami S (2024) Identification of miR-125a and miR-106b signature as a potential diagnostic biomarker in breast cancer tissues. Pathol Res Pract 256:155277","journal-title":"Pathol Res Pract"},{"issue":"8","key":"11656_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B et al (2017) UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 19(8):649\u2013658","journal-title":"Neoplasia"},{"issue":"1","key":"11656_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68758-0","volume":"14","author":"GM Salum","year":"2024","unstructured":"Salum GM, Elaraby NM, Ahmed HA, Abd El Meguid M, Fotouh BE, Ashraf M et al (2024) Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: a retrospective, exploratory analysis. Sci Rep 14(1):29757","journal-title":"Sci Rep"},{"key":"11656_CR16","first-page":"19","volume":"23","author":"C Zhang","year":"2022","unstructured":"Zhang C, Sun C, Zhao Y, Wang Q, Guo J, Ye B et al (2022) Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021. Int J Mol Sci 23:19","journal-title":"Int J Mol Sci"},{"key":"11656_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030651","author":"RP Arun","year":"2022","unstructured":"Arun RP, Cahill HF, Marcato P (2022) Breast cancer subtype-specific miRNAs: networks, impacts, and the potential for intervention. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030651","journal-title":"Biomedicines"},{"key":"11656_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/978-3-031-63657-8_20","volume":"1460","author":"AB Engin","year":"2024","unstructured":"Engin AB, Engin A (2024) Micrornas as epigenetic regulators of obesity. Adv Exp Med Biol 1460:595\u2013627","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"11656_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00264-9","volume":"6","author":"Y Kong","year":"2025","unstructured":"Kong Y, Yang H, Nie R, Zhang X, Zuo F, Zhang H et al (2025) Obesity: pathophysiology and therapeutic interventions. Mol Biomed 6(1):25","journal-title":"Mol Biomed"},{"key":"11656_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47100799","author":"S Sultan","year":"2025","unstructured":"Sultan S, Maashi M (2025) Obesity alters the microRNA expression profile related to metabolic disorders in peripheral blood mononuclear cells: preliminary results. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47100799","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"11656_CR21","doi-asserted-by":"publisher","first-page":"e24010","DOI":"10.1002\/jcla.24010","volume":"35","author":"M Mahmoudian","year":"2021","unstructured":"Mahmoudian M, Razmara E, Mahmud Hussen B, Simiyari M, Lotfizadeh N, Motaghed H et al (2021) Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues. J Clin Lab Anal 35(11):e24010","journal-title":"J Clin Lab Anal"},{"key":"11656_CR22","doi-asserted-by":"crossref","unstructured":"Hussen BM, Abdullah ST, Rasul MF, Salihi A, Ghafouri-Fard S, Hidayat HJ et al (2021) MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets. Front Mol Biosci. ;Volume 8\u20132021","DOI":"10.3389\/fmolb.2021.764025"},{"issue":"12","key":"11656_CR23","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1373\/clinchem.2010.147553","volume":"56","author":"C Zhang","year":"2010","unstructured":"Zhang C, Wang C, Chen X, Yang C, Li K, Wang J et al (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56(12):1871\u20131879","journal-title":"Clin Chem"},{"issue":"7","key":"11656_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/1541-7786.MCR-10-0529","volume":"9","author":"X Li","year":"2011","unstructured":"Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M et al (2011) Mirna-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9(7):824\u201333","journal-title":"Mol Cancer Res"},{"issue":"36","key":"11656_CR25","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1200\/JCO.2011.38.2697","volume":"29","author":"J Zhou","year":"2011","unstructured":"Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z et al (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29(36):4781\u20138","journal-title":"J Clin Oncol"},{"issue":"17","key":"11656_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.297.17.1901","volume":"297","author":"M Bloomston","year":"2007","unstructured":"Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP et al (2007) Microrna expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17):1901\u20138","journal-title":"JAMA"},{"issue":"7","key":"11656_CR27","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/ijc.26177","volume":"130","author":"X Chen","year":"2012","unstructured":"Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C et al (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130(7):1620\u20131628","journal-title":"Int J Cancer"},{"issue":"3","key":"11656_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/1759-7714.14284","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shi S, Wang Y, Zhang X, Liu X, Li J et al (2022) Mir-223-3p targets FBXW7 to promote epithelial-mesenchymal transition and metastasis in breast cancer. Thorac Cancer 13(3):474\u201382","journal-title":"Thorac Cancer"},{"issue":"3","key":"11656_CR29","doi-asserted-by":"publisher","first-page":"e33919","DOI":"10.1371\/journal.pone.0033919","volume":"7","author":"W Kang","year":"2012","unstructured":"Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW et al (2012) Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS ONE 7(3):e33919","journal-title":"PLoS ONE"},{"issue":"10","key":"11656_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.exphem.2015.05.018","volume":"43","author":"B Gentner","year":"2015","unstructured":"Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T et al (2015) Microrna-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol 43(10):858\u201368.e7","journal-title":"Exp Hematol"},{"issue":"3","key":"11656_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23096","volume":"34","author":"G Yu","year":"2020","unstructured":"Yu G, Yin Z, He H, Zheng Z, Chai Y, Xuan L et al (2020) Low serum miR-223 expression predicts poor outcome in patients with acute myeloid leukemia. J Clin Lab Anal 34(3):e23096","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"11656_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"X Wang","year":"2021","unstructured":"Wang X, He Y, Mackowiak B, Gao B (2021) Micrornas as regulators, biomarkers and therapeutic targets in liver diseases. Gut 70(4):784\u2013795","journal-title":"Gut"},{"issue":"1","key":"11656_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-016-0888-7","volume":"14","author":"G Yu","year":"2016","unstructured":"Yu G, Chen X, Chen S, Ye W, Hou K, Liang M (2016) Mir-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J Transl Med 14(1):122","journal-title":"J Transl Med"},{"issue":"6","key":"11656_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.bcp.2009.10.017","volume":"79","author":"Z Liang","year":"2010","unstructured":"Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K et al (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79(6):817\u201324","journal-title":"Biochem Pharmacol"},{"key":"11656_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.biopha.2018.09.053","volume":"108","author":"X Liang","year":"2018","unstructured":"Liang X, Li Z, Men Q, Li Y, Li H, Chong T (2018) Mir-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1. Biomed Pharmacother 108:574\u2013583","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"11656_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/08977194.2015.1076406","volume":"33","author":"Y Li","year":"2015","unstructured":"Li Y, Gao Y, Xu Y, Ma H, Yang M (2015) Down-regulation of miR-326 is associated with poor prognosis and promotes growth and metastasis by targeting FSCN1 in gastric cancer. Growth Factors 33(4):267\u2013274","journal-title":"Growth Factors"},{"issue":"2","key":"11656_CR37","first-page":"173","volume":"6","author":"R Wang","year":"2016","unstructured":"Wang R, Chen X, Xu T, Xia R, Han L, Chen W et al (2016) MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res 6(2):173\u2013186","journal-title":"Am J Cancer Res"},{"issue":"Suppl 4","key":"11656_CR38","doi-asserted-by":"publisher","first-page":"S767","DOI":"10.1245\/s10434-014-4009-7","volume":"21","author":"CM Su","year":"2014","unstructured":"Su CM, Su YH, Chiu CF, Chang YW, Hong CC, Yu YH et al (2014) Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma. Ann Surg Oncol 21(Suppl 4):S767\u2013S775","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"11656_CR39","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1111\/1759-7714.13620","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang L, Liu Q, Mu Q, Zhou D, Li H, Zhang B et al (2020) MiR-429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt\/\u03b2-catenin signaling pathway. Thorac Cancer 11(11):3126\u201338","journal-title":"Thorac Cancer"},{"issue":"18","key":"11656_CR40","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.18632\/aging.205051","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Meng X, Luo Y, Luo S, Li J, Zeng J et al (2023) The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1. Aging 15(18):9809\u201321","journal-title":"Aging"},{"issue":"1","key":"11656_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7150\/thno.36274","volume":"10","author":"C Cava","year":"2020","unstructured":"Cava C, Novello C, Martelli C, Lodico A, Ottobrini L, Piccotti F et al (2020) Theranostic application of miR-429 in HER2\u2009+\u2009breast cancer. Theranostics 10(1):50\u201361","journal-title":"Theranostics"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11656-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:46:27Z","timestamp":1775029587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11656-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11656"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11656-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were in agreement with the ethical guidelines of the national research committee and with the 1964 Helsinki declaration and its subsequent modifications. Informed consent forms were acquired from all participants. The study protocol was verified by the ethical committee of Shahid Beheshti University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}}],"article-number":"570"}}